Avenue Therapeutics, Inc.
ATXI
$0.58
-$0.01-1.70%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -38.76% | 44.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -41.89% | 19.36% | |||
| Operating Income | 115.59% | -19.36% | |||
| Income Before Tax | 117.71% | -19.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 117.71% | -19.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | -60.00% | |||
| Net Income | 118.09% | -19.95% | |||
| EBIT | 115.59% | -19.36% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 116.88% | -116.26% | |||
| Normalized Basic EPS | 117.10% | 23.17% | |||
| EPS Diluted | 116.88% | -116.26% | |||
| Normalized Diluted EPS | 117.10% | 23.17% | |||
| Average Basic Shares Outstanding | 7.16% | 56.75% | |||
| Average Diluted Shares Outstanding | 7.16% | 56.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||